Interestingly, and in way consistently with CXCR7 reversion of the poor outcome associated with CXCR4 expression in DLBCL and with CXCR7 acting by inhibiting CXCR4 signaling in this tumor type, in normal B-cells CXCR7 acts as an active scavenger of CXCL12 and attenuates CXCR4-mediated and CXCL12-dependent migration [32,33]. The gene discussed is CXCR4; the disease is neoplasm.